SRR1363633
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.564
- TNFA_SIGNALING_VIA_NFKB+0.564
- IL6_JAK_STAT3_SIGNALING+0.539
- INFLAMMATORY_RESPONSE+0.514
- IL2_STAT5_SIGNALING+0.435
- COAGULATION+0.401
- APOPTOSIS+0.397
- ANGIOGENESIS+0.388
- INTERFERON_GAMMA_RESPONSE+0.388
- COMPLEMENT+0.380
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.330
- OXIDATIVE_PHOSPHORYLATION-0.314
- DNA_REPAIR-0.246
- MITOTIC_SPINDLE-0.179
- G2M_CHECKPOINT-0.152
- UV_RESPONSE_DN-0.137
- E2F_TARGETS-0.130
- MYC_TARGETS_V2-0.126
- SPERMATOGENESIS-0.117
- KRAS_SIGNALING_DN-0.108
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1350525 | GTEX | — | 0.941 |
| 2 | SRR1368856 | GTEX | — | 0.935 |
| 3 | SRR1446828 | GTEX | — | 0.908 |
| 4 | SRR1468403 | GTEX | — | 0.905 |
| 5 | SRR1488538 | GTEX | — | 0.905 |
| 6 | SRR660895 | GTEX | — | 0.904 |
| 7 | SRR1388007 | GTEX | — | 0.902 |
| 8 | SRR1338584 | GTEX | — | 0.891 |
| 9 | SRR1488836 | GTEX | — | 0.891 |
| 10 | SRR1440356 | GTEX | — | 0.889 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.564 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.564 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.539 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.514 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.435 | Idelalisib | — uncovered |
| COAGULATION | 0.401 | Binimetinib | — uncovered |
| APOPTOSIS | 0.397 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.388 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.388 | Idelalisib | — uncovered |
| COMPLEMENT | 0.380 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.363 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.355 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.353 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.345 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.322 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.314 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.287 | Inavolisib | — uncovered |
| HYPOXIA | 0.278 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.261 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.259 | Inavolisib | — uncovered |